Cargando…
Almost Complete Response with a Single Administration (225)Ac-DOTATATE in a Patient with a Metastatic Neuroendocrine Tumor of Unknown Primary
Neuroendocrine tumors (NETs) are being seen increasingly frequently, and the only known curative treatment method is surgical resection. Peptide receptor radionuclide therapy (PRRT) is a treatment option that the most contributes to progression-free survival and overall survival in metastatic cases....
Autores principales: | Alan Selçuk, Nalan, Demirci, Emre, Ocak, Meltem, Toklu, Türkay, Ergen, Selçuk, Kabasakal, Levent |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Galenos Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9246299/ https://www.ncbi.nlm.nih.gov/pubmed/35771003 http://dx.doi.org/10.4274/mirt.galenos.2022.64497 |
Ejemplares similares
-
Initial Findings on the Use of [(225)Ac]Ac-DOTATATE Therapy as a Theranostic Application in Patients with Neuroendocrine Tumors
por: Demirci, Emre, et al.
Publicado: (2023) -
Lu-177-PSMA-617 Prostate-Specific Membrane Antigen Inhibitor Therapy in Patients with Castration-Resistant Prostate Cancer: Stability, Bio-distribution and Dosimetry
por: Kabasakal, Levent, et al.
Publicado: (2017) -
Successful Combination of Olaparib and (225)Ac-Dotatate in a Patient with Neuroendocrine Tumor G3 and BRCA Mutation
por: Kröcher, Anke, et al.
Publicado: (2023) -
Testicular Metastasis of Jejunal Neuroendocrine Tumor on (68)Ga-DOTATATE PET/CT
por: Şahin, Ömer Faruk, et al.
Publicado: (2023) -
Ileal Neuroendocrin Tumor Metastasis to Breast Diagnosed with Ga-68 DOTATATE PET/CT
por: Sağlampınar Karyağar, Sevda, et al.
Publicado: (2019)